ArticleCureus2026
Adult-Onset Alagille Syndrome Presenting With Recurrent Cholestasis: A Rare Genetic Diagnosis Confirmed by Whole Exome Sequencing.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alagille syndrome, also known as arteriohepatic dysplasia, is a multisystem genetic disorder inherited in an autosomal dominant pattern. It is primarily caused by mutations in the Jagged canonical Notch ligand 1 (JAG1) gene and is classically diagnosed in childhood with cholestasis due to bile duct paucity. Adult presentation is rare owing to its incomplete penetrance and milder phenotypes. We report a case of a 33-year-old male with recurrent cholestasis and no prior history of childhood jaundice. Common acquired etiologies were excluded, and comprehensive evaluation revealed a JAG1 mutation by whole exome sequencing (WES). Multiorgan screening showed no extrahepatic involvement. Treatment with ursodeoxycholic acid (UDCA) and supportive therapy led to clinical and biochemical resolution. This case emphasizes the significance of considering rare genetic disorders in adults with unexplained recurrent cholestasis and highlights the value of molecular diagnostics such as whole exome sequencing in facilitating timely diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.